Committee for Japanese Pediatric Guideline for Childhood Asthma, Japanese Society of Pediatric Allergy and Clinical Immunology, Japanese Society of Allergology. Japanese guidelines for childhood asthma 2020.
-
- Arakawa Hirokazu
- Department of Pediatrics, Gunma University Graduate School of Medicine
-
- Adachi Yuichi
- Department of Pediatrics, University of Toyama
-
- Ebisawa Motohiro
- Department of Allergy, Clinical Research Center for Allergology and Rheumatology, National Hospital Organization, Sagamihara National Hospital
-
- Fujisawa Takao
- National Hospital Organization, Mie National Hospital
書誌事項
- タイトル別名
-
- Japanese guidelines for childhood asthma 2020
- Committee for Japanese Pediatric Guideline for Childhood Asthma, Japanese Society of Pediatric Allergy and Clinical Immunology, et al. Japanese guidelines for childhood asthma 2020
この論文をさがす
説明
<p>The Japanese Guideline for Childhood Asthma (JGCA) 2020 is a translation of the Japanese Pediatric Guideline for the Treatment and Management of Asthma (JPGL) 2017 into English, which was published by the Japanese Society of Pediatric Allergy and Clinical Immunology. It makes recommendations for best practices in the management of childhood asthma, including management of acute exacerbations and non-pharmacological and pharmacological management. These guidelines will be of interest to non-specialist physicians involved in the care of children with asthma. In JPGL, JPGL2017 is the first evidence-based guidelines updated according to the GRADE system and Minds approach, and it addresses eight clinical questions about the treatment of childhood asthma. In children aged ≤5 years, infant and preschool asthma is diagnosed according to the response to short acting beta2 agonists or the effect of a therapeutic trial during 1 month with controller treatment and worsening after treatment cessation. Long-term management both promotes pharmacological therapy and measures against risk factors that induce exacerbation, better patient education and a partnership with trinity. In addition, long-term management should not be carried out without review but rather be based on a cycle of evaluation, adjustment and treatment. In JPGL2017, the transdermal patch and oral beta2 agonists are positioned as drugs within the concept of “short-term additional treatment” to be used until the symptoms are stabilized when the control state transiently deteriorates.</p>
収録刊行物
-
- Allergology International
-
Allergology International 69 (3), 314-330, 2020
一般社団法人日本アレルギー学会
